Hyunwoo Oh1, Dae Won Jun2, I-Heng Lee3, Hyun Jung Ahn4, Bo Ok Kim4, Sungeun Jung4, Mindie H Nguyen5. 1. Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea. 2. Department of Internal Medicine, Hanyang University Hospital, Seoul, South Korea. 3. Gilead Sciences Inc, Foster City, CA, USA. 4. Health Division, Kantar, Seoul, South Korea. 5. Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
Abstract
BACKGROUND: It is controversial whether chronic hepatitis B (CHB) patients have more non-liver comorbidities than non-CHB subjects. AIM: To characterise the demographics, comorbidity and health utilisation of CHB patients in South Korea and compare them to matched controls. METHODS: Using the Health Insurance Review & Assessment Service (HIRA) 2007-2016 database, adult patients with claims for CHB analysed. CHB cases and non-CHB controls matched in a 1:4 ratio using propensity score matching method. RESULTS: The age of CHB patients significantly increased from a mean 46.9 years in 2007 to 52.3 years in 2016. The proportions of persons having both liver-related and non-liver related comorbidities were higher in CHB patients compared to matched controls (dyslipidaemia [37.23% vs 23.77%, P < 0.0001], hypertension [29.39% vs 25.27%, P < 0.0001] chronic kidney disease (CKD) [3.02% vs 1.14%, P < 0.0001] and osteoporosis/fracture [OF] [4.09% vs 3.23%, P < 0.0001]). Approximately 50% of CHB patients had more than one comorbidity among CKD, diabetes, DLP, and OF. The odds of CKD in CHB patients were 1.42 times higher, and the odds of OF in CHB patients were 1.09 times higher than matched controls after adjustment for confounders (P < 0.0001). CONCLUSION: Prevalence of liver as well as non-liver comorbidities in patients with CHB was higher than matched controls and increased over time.
BACKGROUND: It is controversial whether chronic hepatitis B (CHB) patients have more non-liver comorbidities than non-CHB subjects. AIM: To characterise the demographics, comorbidity and health utilisation of CHB patients in South Korea and compare them to matched controls. METHODS: Using the Health Insurance Review & Assessment Service (HIRA) 2007-2016 database, adult patients with claims for CHB analysed. CHB cases and non-CHB controls matched in a 1:4 ratio using propensity score matching method. RESULTS: The age of CHB patients significantly increased from a mean 46.9 years in 2007 to 52.3 years in 2016. The proportions of persons having both liver-related and non-liver related comorbidities were higher in CHB patients compared to matched controls (dyslipidaemia [37.23% vs 23.77%, P < 0.0001], hypertension [29.39% vs 25.27%, P < 0.0001] chronic kidney disease (CKD) [3.02% vs 1.14%, P < 0.0001] and osteoporosis/fracture [OF] [4.09% vs 3.23%, P < 0.0001]). Approximately 50% of CHB patients had more than one comorbidity among CKD, diabetes, DLP, and OF. The odds of CKD in CHB patients were 1.42 times higher, and the odds of OF in CHB patients were 1.09 times higher than matched controls after adjustment for confounders (P < 0.0001). CONCLUSION: Prevalence of liver as well as non-liver comorbidities in patients with CHB was higher than matched controls and increased over time.
Authors: Rosyli F Reveron-Thornton; Margaret L P Teng; Eunice Yewon Lee; Andrew Tran; Sean Vajanaphanich; Eunice X Tan; Sanjna N Nerurkar; Rui Xin Ng; Readon Teh; Debi Prasad Tripathy; Takanori Ito; Taku Tanaka; Nozomi Miyake; Biyao Zou; Connie Wong; Hidenori Toyoda; Carlos O Esquivel; C Andrew Bonham; Mindie H Nguyen; Daniel Q Huang Journal: Hepatol Commun Date: 2022-03-02